In this non-randomized retrospective study, statistically significant differences were found in the prevalence of complications (diabetes mellitus) and serum IL-17A (Supplemental Table S1); meanwhile, disease activity did not differ between the TNF-i-treated and IL-17-i-treated groups. Here, TNF is linked to diabetes mellitus.